TRACON Pharmaceuticals Reports Ongoing Complete Response in Choriocarcinoma Patient Treated With Company’s TRC105 in Compassionate Use Phase 2 Clinical Trial Conducted at Dana-Farber Cancer Institute

SAN DIEGO, Sept. 18, 2015 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced results from two oral presentations, one by Dr. Kevin Elias and… Continue Reading

Cesca Therapeutics Reports Fiscal Year 2015 Results

Notes Significant Advances in Leading Clinical Programs Management Will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) RANCHO CORDOVA, Calif., Sept. 17, 2015 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the fourth quarter and year… Continue Reading

American CareSource Announces New Ticker Symbol “GNOW”

ATLANTA, Sept. 17, 2015 (GLOBE NEWSWIRE) — American CareSource Holdings, Inc. (NASDAQ:ANCI), a high-growth, urgent and primary care company operating under the name GoNow Doctors, announced today that its NADSAQ ticker will change to “GNOW”. The new symbol is anticipated to become effective as of the opening of… Continue Reading

UPDATE: Photo Release — Nasdaq Welcomes REGENXBIO Inc. to The Nasdaq Stock Market

NEW YORK, Sept. 17, 2015 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq:NDAQ) announced that trading of REGENXBIO Inc. (Nasdaq:RGNX) commenced on The Nasdaq Stock Market on September 17, 2015. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1e31f519-81c7-43f7-b46e-8056c1f85d24 REGENXBIO Inc. is a leading biotechnology company focused on the development, commercialization and… Continue Reading